Bradley L. Campbell - Nov 6, 2024 Form 4 Insider Report for AMICUS THERAPEUTICS, INC. (FOLD)

Role: President and CEO, Director
Signature: /s/ Christian Formica, Attorney-in-Fact
Stock symbol: FOLD
Transactions as of: Nov 6, 2024
Transactions value $: -$1,776
Form type: 4
Date filed: 11/7/2024, 05:49 PM
Previous filing: Nov 4, 2024

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	FOLD	Common Stock	Options Exercise	$97K	+7.9K	+0.89%	$12.28	895K	Nov 6, 2024	Direct
transaction	FOLD	Common Stock	Sale	-$98.8K	-7.9K	-0.88%	$12.50	887K	Nov 6, 2024	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	FOLD	Stock Options (right to buy)	Options Exercise	$0	-7.9K	-10.53%	$0.00	67.1K	Nov 6, 2024	Common Stock	7.9K	$12.28	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id	Content
F1	This price is the weighted average price for the transactions reported on this line. The prices for the transactions reported on this line range from $12.50 to $12.57 inclusive. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F2	All of the options were fully vested and exercisable as of the transaction date.

Content

This price is the weighted average price for the transactions reported on this line. The prices for the transactions reported on this line range from $12.50 to $12.57 inclusive. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

All of the options were fully vested and exercisable as of the transaction date.

Remarks:

All transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 23, 2023.